Cytotoxic T-Lymphocyte Antigen 4
CTLA4geneCTLA4 suppresses T-cell co-stimulation post-MI, reducing excessive adaptive immune inflammation and plaque destabilization.
Pathway placement
Cascade stepPlaque inflammation
Confidencemedium
RationaleT-cell checkpoint inhibitor; post-MI immune regulation and inflammation dampening.
Druggability
DruggableYes
Known drugs / candidates6
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000163599
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I51
C — confounder / Type-II88
A — assay feasibility52
E — evidence strength33
T1DI (composite)5
Specificity differential (R−C)-37.4
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Whole blood — gene is not a circulating analyte; measure protein product or genotype
Collection tube
K2-EDTA whole blood (lavender-top)
Method / principle
SNP genotyping / sequencing; or immunoassay of encoded protein
Reagent / substrate
Allele-specific primers/probes (TaqMan) or NGS panel; or antibody for protein
Platform
qPCR / NGS / array
Turnaround · availability
Send-out · Genotyping widely available; protein assay variable
Literature evidence(1)
- CTLA-4-Ig therapy preserves cardiac function following myocardial infarction with reperfusion.Cardiovascular research · 2025 · PMID 41039954 · doi